BlueLine Partners

Devices & Diagnostics

Angeion restructures board to quell proxy fight with investor

Troubled diagnostic systems maker Angeion Corp. (NASDAQ: ANGN) has restructured its board of directors to quell a proxy fight with activist shareholder BlueLine Partners LLC. Danville, California-based BlueLine Partners, which owns 7.2 percent of Angeion's outstanding shares, was gathering shareholder signatures in an effort to remove Angeion's directors --whose "advice and consent" style of corporate governance is failing to turn around the company -- and replace them with a new board nominated by shareholders.

By Mary Vanac
Devices & Diagnostics

Angeion shareholder blasts company, wants to oust board

A shareholder of struggling  Angeion Corp. (Nasdaq: ANGN) blasted the company for poor performance and seeks to rally other shareholders in an effort to oust the Minnesota device company’s board. Danville, California-based BlueLine Partners, which owns 7.2 percent of Angeion’s outstanding shares, is attempting to gather signatures from other shareholders in an effort to remove […]

By Brandon Glenn
sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab